Most glioblastoma tumors are marked by one or two broad mutation patterns, but about 20 percent of the lethal brain tumors have biomarkers that cannot be identified.  Now scientists at Duke Cancer Institute have identified mutations for the vast majority of the remaining 20 percent of uncharacterized tumors, which tend to be especially lethal. The findings indicate that these mutations […]

Continue reading »